BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jiao TY, Ma YD, Guo XZ, Ye YF, Xie C. Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease. Acta Pharmacol Sin 2022;43:1103-19. [PMID: 35217817 DOI: 10.1038/s41401-022-00880-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhou S, You H, Qiu S, Yu D, Bai Y, He J, Cao H, Che Q, Guo J, Su Z. A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR). Biomed Pharmacother 2022;154:113577. [PMID: 35988420 DOI: 10.1016/j.biopha.2022.113577] [Reference Citation Analysis]
2 Mori H, Svegliati Baroni G, Marzioni M, Di Nicola F, Santori P, Maroni L, Abenavoli L, Scarpellini E. Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota. Metabolites 2022;12:647. [DOI: 10.3390/metabo12070647] [Reference Citation Analysis]
3 Xu HE, Guo JS. All about NASH: disease biology, targets, and opportunities on the road to NASH drugs. Acta Pharmacol Sin 2022;43:1101-2. [PMID: 35379932 DOI: 10.1038/s41401-022-00900-y] [Reference Citation Analysis]